Scholar Rock (NASDAQ:SRRK) Raised to "Strong-Buy" at Lifesci Capital

Lifesci Capital upgraded shares of Scholar Rock (NASDAQ:SRRK - Free Report) to a strong-buy rating in a report released on Tuesday morning,Zacks.com reports. Lifesci Capital also issued estimates for Scholar Rock's Q2 2025 earnings at ($0.92) EPS, Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($0.87) EPS, FY2025 earnings at ($3.29) EPS, Q1 2026 earnings at ($0.65) EPS, Q2 2026 earnings at ($0.57) EPS, Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.15) EPS and FY2026 earnings at ($1.59) EPS.

Separately, Wedbush reiterated an "outperform" rating and set a $50.00 target price on shares of Scholar Rock in a research report on Wednesday, May 14th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $42.67.

Scholar Rock Stock Performance

NASDAQ:SRRK traded up $3.43 during mid-day trading on Tuesday, hitting $34.25. The stock had a trading volume of 2,541,941 shares, compared to its average volume of 1,275,156. Scholar Rock has a twelve month low of $6.76 and a twelve month high of $46.98. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. The stock has a market cap of $3.25 billion, a price-to-earnings ratio of -14.57 and a beta of 0.37. The company's 50 day simple moving average is $30.25 and its 200 day simple moving average is $36.05.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same period last year, the company earned ($0.59) EPS. On average, equities research analysts forecast that Scholar Rock will post -2.42 earnings per share for the current year.

Insiders Place Their Bets

In other Scholar Rock news, insider Akshay Vaishnaw sold 6,750 shares of Scholar Rock stock in a transaction dated Thursday, May 29th. The stock was sold at an average price of $29.72, for a total transaction of $200,610.00. Following the transaction, the insider now directly owns 616,205 shares of the company's stock, valued at approximately $18,313,612.60. The trade was a 1.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Edward H. Myles sold 142,292 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $35.62, for a total transaction of $5,068,441.04. Following the sale, the chief financial officer now owns 111,345 shares of the company's stock, valued at approximately $3,966,108.90. This trade represents a 56.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 181,798 shares of company stock valued at $6,284,738. 13.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Scholar Rock

Large investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. grew its stake in Scholar Rock by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 2,396 shares of the company's stock valued at $77,000 after acquiring an additional 430 shares during the period. CWM LLC raised its stake in shares of Scholar Rock by 152.8% during the 1st quarter. CWM LLC now owns 996 shares of the company's stock worth $32,000 after purchasing an additional 602 shares during the period. Amalgamated Bank grew its position in shares of Scholar Rock by 30.6% during the 4th quarter. Amalgamated Bank now owns 2,643 shares of the company's stock valued at $114,000 after acquiring an additional 620 shares during the period. Global Retirement Partners LLC increased its position in Scholar Rock by 584.7% in the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock worth $39,000 after buying an additional 766 shares during the last quarter. Finally, Corebridge Financial Inc. lifted its holdings in Scholar Rock by 2.2% during the first quarter. Corebridge Financial Inc. now owns 39,389 shares of the company's stock valued at $1,266,000 after purchasing an additional 850 shares during the last quarter. Institutional investors and hedge funds own 91.08% of the company's stock.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.